ReviewFrontiers in oncology2025
Preoperative radiotherapy in patients with locally advanced esophageal squamous cell carcinoma: a narrative review.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoadjuvant treatments play a crucial role in improving survival rates for patients with locally advanced resectable esophageal cancer. The CROSS and NEOCRTEC5010 trials have shown that neoadjuvant concurrent chemoradiotherapy significantly enhances survival compared to surgery alone. In contrast, the NeoRes and CMISG1701 trials indicate that while neoadjuvant chemoradiotherapy yields a higher histological complete response rate, it does not confer survival benefits over neoadjuvant chemotherapy. The recent JCOG1109 trial has demonstrated that neoadjuvant triplet chemotherapy offers a statistically significant overall survival advantage compared to doublet chemotherapy. However, combining doublet chemotherapy with radiotherapy did not show notable survival improvement compared to doublet chemotherapy alone. Additionally, neoadjuvant immunotherapy in conjunction with chemotherapy has shown a greater histological complete response rate compared to neoadjuvant chemotherapy, with comparable rates to neoadjuvant chemoradiotherapy. These findings have sparked debate regarding the necessity of radiotherapy in neoadjuvant treatment protocols. This review aims to elucidate the role of radiotherapy based on the current evidence and to assess ongoing and future trials that may address existing knowledge gaps. It will also underscore the challenges in making definitive recommendations about radiotherapy, particularly as technologies and treatment modalities continue to advance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.